Product Information
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is a generic product labeled by Strides Pharma Inc., priced at $0.4508 per EA under NDC 64380071904. Its NADAC has been published 263 times since May 12, 2021.
FDA first approved this application on Jan 13, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB
EMTRICITABINE and TENOFOVIR Disoproxil FumarateStrength
200; 300 mg/1; mg/1
Manufacturer
Strides Pharma Inc.NDC
64380071904
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA091055FDA Approved
1/13/2021
TE Code
AB
On Market Since
3/30/2021
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has been published 263 times since May 12, 2021, and over the history we have for it it has declined 99.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4508 per EA |
|---|---|
| All-time high | $45.8098 (May 12, 2021) |
| All-time low | $0.4258 (May 22, 2024) |
| 52-week high | $0.5904 |
| 52-week low | $0.4508 |
| Median price | $0.5855 |
| Average price | $1.1254 |
| Largest weekly change | -97.1% (Jun 2, 2021) |
| Weeks tracked | 263 |
| Tracking since | May 12, 2021 |
1W
N/A
1M
N/A
3M
N/A
6M
-5.3%
1Y
-23.6%
3Y
-23.5%
5Y
-68.2%
All
-99.0%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, manufactured by Strides Pharma Inc., is $0.4508 per EA (NDC 64380071904), effective May 20, 2026.
How has the price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has declined 99.0%. It has been tracked across 263 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Since May 12, 2021, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has ranged from a low of $0.4258 (May 22, 2024) to a high of $45.8098 (May 12, 2021), with a median of $0.5855 per EA.
Are there cheaper alternatives to EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB (NDC 64380071904) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.